Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment.

Messinis IE, Loutradis D, Domali E, Kotsovassilis CP, Papastergiopoulou L, Kallitsaris A, Drakakis P, Dafopoulos K, Milingos S

Human reproduction (Oxford, England)21 Jul 2005Cited by 36 (Europe PMC)

PMID16037104DOI10.1093/humrep/dei210PepBankPUB-16037104

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women undergoing IVF/ICSI, FSH, LH, estradiol and progesterone showed similar trends with alternate-day and daily ganirelix.
In plain wordsIn women undergoing IVF/ICSI, FSH, LH, estradiol and progesterone showed similar trends with alternate-day and daily ganirelix.
Peptide
Ganirelix
Outcome
Direction not reportedSerum hormone trends
Study
n = 73
Comparator
daily ganirelix
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg each · until the day of HCG administrationAs given in this study (human).
Source sentences
Summary
Serum FSH, LH, estradiol and progesterone values showed similar trends in the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized controlled trial was designed to evaluate whether a GnRH antagonist given every other day could prevent premature luteinization in women undergoing IVF/ICSI treatment.
Summary · context
A total of 73 women receiving ovulation stimulation IVF cycles with recombinant FSH were allocated randomly on cycle day 7 to GnRH antagonist ganirelix in multiple doses (0.25 mg each), either daily (n = 37 women, group 1) or every other day (n = 36 women, group 2) until the day of HCG administration.
Report a problemFND-1603710401
02HumanRandomized controlled trialEfficacy outcome
In stimulated IVF cycles, LH rises occurred in 14 women (39%) with alternate-day ganirelix versus 13 (35%) with daily ganirelix.
In plain wordsIn stimulated IVF cycles, LH rises occurred in 39% with alternate-day ganirelix versus 35% with daily ganirelix.
Peptide
Ganirelix
Outcome
Direction not reportedPremature LH rises during FSH stimulation
Study
n = 73
Comparator
daily ganirelix
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg each · until the day of HCG administrationAs given in this study (human).
Measurements
Women with premature LH rise during FSH stimulation
14 women
alternate-day ganirelix
Women with premature LH rise during FSH stimulation
39%
alternate-day ganirelix
Women with premature LH rise during FSH stimulation
13 women
daily ganirelix
Women with premature LH rise during FSH stimulation
35%
daily ganirelix
Source sentences
Summary
During FSH stimulation, 13 (35%) of the women in group 1 had premature LH rises (> or = 10 IU/l) of which eight (22%) were after the start of antagonist administration. In group 2 there were 14 (39%) LH rises during FSH stimulation of which 10 (28%) were after the start of antagonist administration.
3 context sentences(design, population, supporting numbers)
Summary · context
During FSH stimulation, 13 (35%) of the women in group 1 had premature LH rises (> or = 10 IU/l) of which eight (22%) were after the start of antagonist administration.
Summary · context
This randomized controlled trial was designed to evaluate whether a GnRH antagonist given every other day could prevent premature luteinization in women undergoing IVF/ICSI treatment.
Summary · context
A total of 73 women receiving ovulation stimulation IVF cycles with recombinant FSH were allocated randomly on cycle day 7 to GnRH antagonist ganirelix in multiple doses (0.25 mg each), either daily (n = 37 women, group 1) or every other day (n = 36 women, group 2) until the day of HCG administration.
Report a problemFND-1603710402
03HumanRandomized controlled trialEfficacy outcome
In stimulated IVF cycles, LH rises after ganirelix initiation occurred in 10 women (28%) with alternate-day dosing versus eight (22%) with daily dosing.
In plain wordsIn stimulated IVF cycles, LH rises after ganirelix initiation occurred in 28% with alternate-day dosing versus 22% with daily dosing.
Peptide
Ganirelix
Outcome
Direction not reportedLH rises after antagonist initiation
Study
n = 73
Comparator
daily ganirelix
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg each · until the day of HCG administrationAs given in this study (human).
Measurements
Women with LH rise after antagonist start
10 women
alternate-day ganirelix
Women with LH rise after antagonist start
28%
alternate-day ganirelix
Women with LH rise after antagonist start
8 women
daily ganirelix
Women with LH rise after antagonist start
22%
daily ganirelix
Source sentences
Summary
During FSH stimulation, 13 (35%) of the women in group 1 had premature LH rises (> or = 10 IU/l) of which eight (22%) were after the start of antagonist administration. In group 2 there were 14 (39%) LH rises during FSH stimulation of which 10 (28%) were after the start of antagonist administration.
3 context sentences(design, population, supporting numbers)
Summary · context
During FSH stimulation, 13 (35%) of the women in group 1 had premature LH rises (> or = 10 IU/l) of which eight (22%) were after the start of antagonist administration.
Summary · context
This randomized controlled trial was designed to evaluate whether a GnRH antagonist given every other day could prevent premature luteinization in women undergoing IVF/ICSI treatment.
Summary · context
A total of 73 women receiving ovulation stimulation IVF cycles with recombinant FSH were allocated randomly on cycle day 7 to GnRH antagonist ganirelix in multiple doses (0.25 mg each), either daily (n = 37 women, group 1) or every other day (n = 36 women, group 2) until the day of HCG administration.
Report a problemFND-1603710403
04HumanRandomized controlled trialEfficacy outcome
In stimulated IVF cycles, luteinization occurred in one woman in each ganirelix dosing group (3%).
In plain wordsIn stimulated IVF cycles, luteinization occurred in one woman in each ganirelix dosing group (3%).
Peptide
Ganirelix
Outcome
No significant changeLuteinization
Study
n = 73
Comparator
daily ganirelix
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg each · until the day of HCG administrationAs given in this study (human).
Measurements
Women with luteinization
1 women
daily ganirelix
Women with luteinization
1 women
alternate-day ganirelix
Luteinization rate overall
3%
each group
Source sentences
Summary
Luteinization (serum progesterone >2 ng/ml) occurred in only one woman in each group overall (3%).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized controlled trial was designed to evaluate whether a GnRH antagonist given every other day could prevent premature luteinization in women undergoing IVF/ICSI treatment.
Summary · context
A total of 73 women receiving ovulation stimulation IVF cycles with recombinant FSH were allocated randomly on cycle day 7 to GnRH antagonist ganirelix in multiple doses (0.25 mg each), either daily (n = 37 women, group 1) or every other day (n = 36 women, group 2) until the day of HCG administration.
Report a problemFND-1603710404
05HumanRandomized controlled trialOther
In stimulated IVF cycles, alternate-day ganirelix required a significantly smaller total antagonist dose than daily ganirelix (P < 0.001).
In plain wordsIn stimulated IVF cycles, alternate-day ganirelix required a smaller total antagonist dose than daily ganirelix.
Peptide
Ganirelix
Outcome
DecreaseTotal ganirelix dose
Study
n = 73
Comparator
daily ganirelix
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg each · until the day of HCG administrationAs given in this study (human).
Source sentences
Summary
A significantly smaller total dose of the antagonist was used in group 2 than in group 1 (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized controlled trial was designed to evaluate whether a GnRH antagonist given every other day could prevent premature luteinization in women undergoing IVF/ICSI treatment.
Summary · context
A total of 73 women receiving ovulation stimulation IVF cycles with recombinant FSH were allocated randomly on cycle day 7 to GnRH antagonist ganirelix in multiple doses (0.25 mg each), either daily (n = 37 women, group 1) or every other day (n = 36 women, group 2) until the day of HCG administration.
Report a problemFND-1603710405
06HumanRandomized controlled trialEfficacy outcome
In stimulated IVF cycles, total FSH dose, oocyte recovery and clinical pregnancy appeared similar between ganirelix schedules, but comparisons lacked power.
In plain wordsIn stimulated IVF cycles, FSH dose, oocyte recovery and pregnancy appeared similar between ganirelix schedules, but comparisons lacked power.
Peptide
Ganirelix
Outcome
Direction not reportedFSH dose, oocyte recovery and pregnancy
Study
n = 73
Comparator
daily ganirelix
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg each · until the day of HCG administrationAs given in this study (human).
Source sentences
Summary
The study did not have power to evaluate differences in total dose of FSH, number of oocytes recovered and clinical pregnancy rate, all of which appeared similar in the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized controlled trial was designed to evaluate whether a GnRH antagonist given every other day could prevent premature luteinization in women undergoing IVF/ICSI treatment.
Summary · context
A total of 73 women receiving ovulation stimulation IVF cycles with recombinant FSH were allocated randomly on cycle day 7 to GnRH antagonist ganirelix in multiple doses (0.25 mg each), either daily (n = 37 women, group 1) or every other day (n = 36 women, group 2) until the day of HCG administration.
Report a problemFND-1603710406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.